Business Description
Bicycle Therapeutics PLC
ISIN : US0887861088
Share Class Description:
FRA:50BA: ADRTotal Employee Number:
288Description
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 36.48 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.07 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -0.2 | |||||
Beneish M-Score | -1.51 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 29 | |||||
3-Year EBITDA Growth Rate | 5.4 | |||||
3-Year EPS without NRI Growth Rate | 5.9 | |||||
3-Year FCF Growth Rate | -0.9 | |||||
3-Year Book Growth Rate | -1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -37.25 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 66.84 | |||||
9-Day RSI | 56.11 | |||||
14-Day RSI | 49.79 | |||||
3-1 Month Momentum % | 3.78 | |||||
6-1 Month Momentum % | -30.18 | |||||
12-1 Month Momentum % | -37.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 12.66 | |||||
Quick Ratio | 12.66 | |||||
Cash Ratio | 11.44 | |||||
Days Sales Outstanding | 0.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -32.4 | |||||
Shareholder Yield % | 2.24 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -383.18 | |||||
Net Margin % | -344.95 | |||||
EBITDA Margin % | -333.09 | |||||
FCF Margin % | -367.56 | |||||
OCF Margin % | -363.67 | |||||
ROE % | -34.31 | |||||
ROA % | -28.45 | |||||
ROIC % | -383.89 | |||||
3-Year ROIIC % | 712.84 | |||||
ROC (Joel Greenblatt) % | -1307.22 | |||||
ROCE % | -30.71 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 9 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 4.63 | |||||
PB Ratio | 0.53 | |||||
Price-to-Tangible-Book | 0.53 | |||||
EV-to-EBIT | 1.14 | |||||
EV-to-EBITDA | 1.17 | |||||
EV-to-Revenue | -3.91 | |||||
EV-to-Forward-Revenue | 0.18 | |||||
EV-to-FCF | 1.07 | |||||
Price-to-GF-Value | 0.29 | |||||
| Price-to-Net-Current-Asset-Value | 0.57 | |||||
| Price-to-Net-Cash | 0.64 | |||||
Earnings Yield (Greenblatt) % | 87.72 | |||||
FCF Yield % | -78.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bicycle Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 54.25 | ||
| EPS (TTM) (€) | -2.713 | ||
| Beta | 0.9908 | ||
| 3-Year Sharpe Ratio | -0.79 | ||
| 3-Year Sortino Ratio | -1.08 | ||
| Volatility % | 42.43 | ||
| 14-Day RSI | 49.79 | ||
| 14-Day ATR (€) | 0.121324 | ||
| 20-Day SMA (€) | 3.474 | ||
| 12-1 Month Momentum % | -37.56 | ||
| 52-Week Range (€) | 3.24 - 7.8 | ||
| Shares Outstanding (Mil) | 69.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bicycle Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bicycle Therapeutics PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-10-30 | In 121 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 37 days | ||
| General meeting for 2026 | 2026-06-17 09:00 | 3.44 (+0.58%) | ||
| First quarter earnings results for 2026 | 2026-04-30 | 3.90 (+1.56%) | ||
| Annual report for 2025 | 2026-03-17 | 4.20 (+3.45%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-17 | 4.20 (+3.45%) | ||
| Jefferies Global Healthcare Conference | 2025-11-18 05:30 | 5.60 (+3.70%) | ||
| Third quarter earnings results for 2025 | 2025-10-30 | 6.80 (-0.73%) | ||
| Morgan Stanley 23rd Annual Global Healthcare Conference | 2025-09-09 07:45 | 5.95 (+0.85%) | ||
| Cantor Global Healthcare Conference | 2025-09-04 15:55 | 6.05 (+0.83%) |
Show
Entries
Bicycle Therapeutics PLC Frequently Asked Questions
What is Bicycle Therapeutics PLC(FRA:50BA)'s stock price today?
The current price of FRA:50BA is €3.56. The 52 week high of FRA:50BA is €7.80 and 52 week low is €3.24.
When is next earnings date of Bicycle Therapeutics PLC(FRA:50BA)?
The next earnings date of Bicycle Therapeutics PLC(FRA:50BA) is 2026-08-07 Est..
Does Bicycle Therapeutics PLC(FRA:50BA) pay dividends? If so, how much?
Bicycle Therapeutics PLC(FRA:50BA) does not pay dividend.
Press Release
Articles on Bicycle Therapeutics PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers